Kiyotaka Yoh

机构：National Cancer Center Hospital East · ORCID：0000-0001-6928-357X

发表论文 490 篇 · 总被引 9695 次 · h-index 48

代表论文

• HER2-Selective Tyrosine Kinase Inhibitor, Zongertinib (BI 1810631), in Patients With Advanced/Metastatic Solid Tumors With HER2 Alterations: A Phase Ia Dose-Escalation Study (2025 · Journal of Clinical Oncology · 被引 49)
• First-Line Zongertinib in Advanced HER2 -Mutant Non–Small-Cell Lung Cancer (2026 · New England Journal of Medicine · 被引 13)
• A phase 1b study of cofetuzumab pelidotin monotherapy in patients with PTK7-expressing recurrent non-small cell lung cancer (2025 · Lung Cancer · 被引 7)
• PT2.12.03 Zongertinib in Patients With Previously Treated HER2-Mutant NSCLC and Brain Metastases at Baseline: Beamion LUNG-1 (2025 · Journal of Thoracic Oncology · 被引 5)
• 491P Zongertinib in HER2-altered gastrointestinal cancers: Preclinical activity and clinical findings from a phase Ia study (2025 · Annals of Oncology · 被引 3)
• Phase 1/2 trial of brigatinib plus panitumumab in patients with osimertinib-resistant EGFR-mutated non-small cell lung cancer harboring EGFR C797S mutation (2026 · Cancer Treatment and Research Communications · 被引 1)